Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Al Serrao who wrote (17370)	3/11/1998 1:57:00 PM
From: Nemer	Read Replies (2) \| Respond to of 50167

Off topic Al: ---->can you still find a decent home in E. Texas thats reasonable or have the home prices skyrocketed like they have here in Dallas? I have several relatives living in and around Big D, so I know what you mean. My sister's house for example will bring more money than mine on the market today. She lives in Addison and hers would fit in a wing of mine ...... Current new construction here is in the $35-$50 buck range per ft, including lot. Regards---Nemer

To: Al Serrao who wrote (17370)	3/11/1998 3:31:00 PM
From: Mackie	Respond to of 50167

EXTI - Taking off today on News ! Tuesday March 10, 2:23 pm Eastern Time Company Press Release Xenogenics Corp. and Loyola University Sign Research Agreement SAN DIEGO--(BW HealthWire)--March 10, 1998--Jim Considine, MD MBA, president, Xenogenics Corp., and John Brems, MD FACS, chairman of the Xenogenics Scientific Advisory Board and director, Transplantation, Loyola University, Chicago Stritch School of Medicine, Tuesday announced that a research agreement has been signed between the two organizations. Loyola will shortly begin preclinical testing of the Sybiol bioartificial liver support technology under the direction of James Filkins, Ph.D., professor emeritus, Loyola University School of Medicine. Dr. Filkins is also a member of the Xenogenics Scientific Advisory Board. The proprietary Sybiol synthetic bioartificial liver (patent pending) is intended to be used as an ''artificial liver'' to support transplant candidates when no organ donor is available. It would also be used for posttransplant stabilization as well as treatment of toxicity secondary to both chronic liver disease and acute hepatotoxic agents. The device is intended to perform a function for the liver similar to that which renal dialysis performs for kidneys. A key difference is the proposed usage of porcine (piglet) hepatocytes (liver cells) to provide continuous, sustained removal of human blood toxins outside the liver. Loyola has recently assembled a team of bioartificial liver researchers including Drs. Brems and Filkins, as well as David Van Thiel, MD FACP, professor, Internal Medicine, Loyola University Medical Center. Dr. Van Thiel was a key architect along with Dr. Thomas Starzl in the development of the liver transplant program at the University of Pittsburgh in the 1980s. Dr. Considine commented, ''The initiation of the research agreement with the liver team at Loyola constitutes an important milestone for Xenogenics Corporation and Exten Industries. We look forward to a long and successful relationship with the Loyola Research Group.'' Xenogenics Corp. is a 100 percent owned subsidiary of Exten Industries Inc. (OTC/BB:EXTI - news) located at 9625 Black Mountain Rd., suite 218, San Diego, 92126-4564. For further information call Jerry Newmin or Barbara Corbett: 619/578-9784 or e-mail at extixeno@aol.com . Exten's Web site is exten.com . The matters set forth in this press release are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report. Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The company disclaims any intent or obligation to update these forward-looking statements. Contact: Xenogenics Corp. Dr. Jim Considine, 714/451-1500 or Exten Industries Inc. W. Gerald Newmin Barbara Corbett, 619/578-9784 after hours: 619/455-7205 619/423-3737